TransCode Therapeutics Inc.

NASDAQ: RNAZ · Real-Time Price · USD
0.43
0.01 (1.94%)
At close: Apr 29, 2025, 11:03 AM

TransCode Therapeutics Statistics

Share Statistics

TransCode Therapeutics has 23.34M shares outstanding. The number of shares has increased by 256.81% in one year.

Shares Outstanding 23.34M
Shares Change (YoY) 256.81%
Shares Change (QoQ) 0%
Owned by Institutions (%) 0.09%
Shares Floating 20.98M
Failed to Deliver (FTD) Shares 188.67K
FTD / Avg. Volume 2.61%

Short Selling Information

The latest short interest is 1.04M, so 4.45% of the outstanding shares have been sold short.

Short Interest 1.04M
Short % of Shares Out 4.45%
Short % of Float 4.45%
Short Ratio (days to cover) 1

Valuation Ratios

The PE ratio is 0 and the forward PE ratio is -0.01. TransCode Therapeutics's PEG ratio is 0.

PE Ratio 0
Forward PE -0.01
PS Ratio 0
Forward PS 1
PB Ratio -0.01
P/FCF Ratio 0
PEG Ratio 0
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for TransCode Therapeutics.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 2.56, with a Debt / Equity ratio of -0.02.

Current Ratio 2.56
Quick Ratio 2.56
Debt / Equity -0.02
Debt / EBITDA 0
Debt / FCF 0
Interest Coverage -584.07

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $0
Profits Per Employee $-2.4M
Employee Count 7
Asset Turnover 0
Inventory Turnover n/a

Taxes

Income Tax 0
Effective Tax Rate 0%

Stock Price Statistics

The stock price has increased by -11.2% in the last 52 weeks. The beta is 1.52, so TransCode Therapeutics's price volatility has been higher than the market average.

Beta 1.52
52-Week Price Change -11.2%
50-Day Moving Average 0.26
200-Day Moving Average 0.29
Relative Strength Index (RSI) 57.58
Average Volume (20 Days) 7.22M

Income Statement

Revenue n/a
Gross Profit 0
Operating Income -15.66M
Net Income -16.79M
EBITDA -14.03M
EBIT -14.57M
Earnings Per Share (EPS) -47.14
Full Income Statement

Balance Sheet

The company has 5.81M in cash and 38.29K in debt, giving a net cash position of 5.77M.

Cash & Cash Equivalents 5.81M
Total Debt 38.29K
Net Cash 5.77M
Retained Earnings -63.2M
Total Assets 7.29M
Working Capital 4.32M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -13.34M and capital expenditures 0, giving a free cash flow of -13.34M.

Operating Cash Flow -13.34M
Capital Expenditures 0
Free Cash Flow -13.34M
FCF Per Share -37.45
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

RNAZ does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for RNAZ is $10, which is 2225.6% higher than the current price. The consensus rating is "Buy".

Price Target $10
Price Target Difference 2225.6%
Analyst Consensus Buy
Analyst Count 1
Stock Forecasts

Stock Splits

The last stock split was on Dec 4, 2024. It was a backward split with a ratio of 1:33.

Last Split Date Dec 4, 2024
Split Type backward
Split Ratio 1:33

Scores

Altman Z-Score -18.9
Piotroski F-Score 2

Advertisement